PMID: 11318077Apr 25, 2001Paper

Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: integrated results from four open-label, multicenter, phase III clinical trials

Clinical Therapeutics
C FogartyR R Williams

Abstract

The rate of macrolide resistance among Streptococcus pneumoniae clinical isolates is rising. Coresistance to several unrelated classes of antimicrobial agents is common and may limit the treatment options available for the management of infections caused by this pathogen. Although the fluoroquinolones appear to retain activity against macrolide-resistant pneumococci, limited clinical data exist to support their use in this setting. This study integrated data from 4 clinical trials to determine whether the fluoroquinolone levofloxacin is an effective therapeutic agent for community-acquired pneumonia (CAP) caused by macrolide-resistant S. pneumoniae. Across the 4 trials, 271 adult patients with CAP were diagnosed with infections caused by S. pneumoniae; these constituted the intent-to-treat population. Clinical isolates obtained from each patient at admission were tested using broth microdilution for in vitro sensitivity to the macrolide erythromycin (minimum inhibitory concentration breakpoints: susceptible, < or =0.25 microg/mL; intermediate, 0.5 microg/mL; resistant, > or =1.0 microg/mL). All patients received levofloxacin (500 mg once daily for 7-14 days) and were analyzed at a posttherapy visit (2-5 days after completion of...Continue Reading

References

Nov 1, 1986·Molecular & General Genetics : MGG·P Courvalin, C Carlier
Dec 14, 1995·The New England Journal of Medicine·J G Bartlett, L M Mundy
Jan 17, 1996·JAMA : the Journal of the American Medical Association·R W PinnerR L Berkelman
Nov 3, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·G V DoernR N Jones
Sep 15, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J G BartlettM J Fine
Sep 15, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·C FogartyK Bush
Jul 13, 2004·Clinical Medicine : Journal of the Royal College of Physicians of London·Wei Shen Lim
Dec 13, 2006·BMJ : British Medical Journal·Graham D Mills, Richard Laing

❮ Previous
Next ❯

Citations

Mar 15, 2012·Current Infectious Disease Reports·Timothy E AlbertsonAndrew L Chan
Nov 1, 2003·Current Therapeutic Research, Clinical and Experimental·Peter Ball
Oct 19, 2002·International Journal of Antimicrobial Agents·Thomas M FileUNKNOWN 546, 547, 548, 549, 550, 551, 556, 557 and 592 Clinical Study Groups
Aug 21, 2002·Expert Opinion on Pharmacotherapy·Steven J MartinSandy J Close
May 1, 2004·Current Therapeutic Research, Clinical and Experimental·Hans H Liu
Apr 2, 2005·Clinics in Chest Medicine·Marcos I Restrepo, Antonio Anzueto
Dec 29, 2004·International Journal of Antimicrobial Agents·José Manuel Querol-RibellesIsidoro Martínez
Jan 7, 2009·Therapeutic Advances in Respiratory Disease·Luis A DíazMarcos I Restrepo
Sep 7, 2018·The Cochrane Database of Systematic Reviews·Jesús López-AlcaldeManuel Gómez-García
Nov 1, 2006·Current Opinion in Infectious Diseases·Marcos I Restrepo, Antonio Anzueto
May 14, 2009·Journal of Food Protection·W M FluckeyM M Brashears
Apr 20, 2002·Current Opinion in Infectious Diseases·M I RestrepoA Anzueto
Nov 16, 2010·Expert Review of Anti-infective Therapy·Brian Wispelwey, Katherine R Schafer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy & Infectious Diseases (ASM)

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Allergy & Infectious Diseases

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.